Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions
American Journal of Respiratory and Critical Care Medicine · 01.06.2026 · 212 (6) · 1100-1114
DOI: 10.1093/ajrccm/aamaf124 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 23.01.2026. Verfasst von Kostas A Papavassiliou und 3 weiteren Autor:innen. Beteiligte Einrichtung: First University Department of Respiratory Medicine, "Sotiria" Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens…. Hauptthemen laut MEDLINE: Lung Neoplasms, Immunotherapy, Small Cell Lung Carcinoma, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with dismal prognosis. Although immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer, their impact in SCLC has been modest, with only 2–3 months’ improvement in median survival. This paradox persists despite SCLC’s high tumor mutational burden, suggesting complex, multifactorial resistance mechanisms. Here we critically review the latest advances in understanding immunotherapy resistance in SCLC. We highlight tumor-intrinsic immune escape mechanisms, including genetic drivers, MHC class I downregulation, and epigenetic repression, as well as the profoundly immunosuppressive tumor microenvironment. We also examine the evolving classification of SCLC into molecular subtypes, which reveals distinct immunogenic landscapes with potential predictive value for immunotherapy response. Importantly, we integrate a comprehensive update on ongoing and recently reported clinical trials that aim to restore immune responsiveness, ranging from combination ICI regimens to novel strategies involving epigenetic modulators, antigen presenting pathway agonists, and bispecific T-cell engagers. Finally, we discuss translational strategies to overcome immunotherapy resistance and outline a precision immunotherapy roadmap, arguing for biomarker-guided and subtype-stratified clinical trial design. By synthesizing mechanistic, translational, and clinical perspectives, this review provides a framework for rational therapeutic innovation in SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First University Department of Respiratory Medicine, "Sotiria" Chest Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
- Section of Cell Biology and Biophysics, Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
ORCID-Profile: Kostas A Papavassiliou, Dimitrios J Stravopodis, Vassiliki A Gogou, Athanasios G Papavassiliou
Zitieren
APA
Papavassiliou, K. A., Stravopodis, D. J., Gogou, V. A., & Papavassiliou, A. G. (2026). Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions. American Journal of Respiratory and Critical Care Medicine, 212(6), 1100-1114. https://doi.org/10.1093/ajrccm/aamaf124
Vancouver
Papavassiliou KA, Stravopodis DJ, Gogou VA, Papavassiliou AG. Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions. American Journal of Respiratory and Critical Care Medicine. 2026;212(6):1100-1114. doi:10.1093/ajrccm/aamaf124
BibTeX
@article{Papavassiliou2026,
author = {Papavassiliou, Kostas A and Stravopodis, Dimitrios J and Gogou, Vassiliki A and Papavassiliou, Athanasios G},
title = {Cracking the code of immunotherapy resistance in small cell lung cancer: molecular insights and emerging solutions},
journal = {American Journal of Respiratory and Critical Care Medicine},
year = {2026},
volume = {212},
number = {6},
pages = {1100--1114},
doi = {10.1093/ajrccm/aamaf124}
}
EUVIMED